Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including without limitation B cell proliferative disorders such as non Hodgkin lymphoma (diffuse large B cell lymphoma follicular lymphoma mantle cell lymphoma or burkitt lymphoma) Waldenstrom macroglobulinemia plasma cell myeloma chronic lymphocytic leukemia lymphoma or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment the pharmaceutical composition contains Ibrutinib a salt prodmg or metabolite thereof microcrystalline cellulose croscamieliose sodium sodium lauryi sulfate and magnesium stearate. In another embodiment the pharmaceutical composition contains Ibrutinib a salt prodrug or metabolite thereof microcrystalline cellulose carboxymethylcellulose sodium hydroxypropylmethylcellulose citric acid monohydrate disodium hy drogen phosphate sucralose sodium methyl parahydroxybenzoate sodium ethyl parahydroxybenzoate concentrated hydrochloric acid sodium hydroxide and water.
